Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.2917
+0.0332 (12.84%)
At close: Sep 12, 2025, 4:00 PM EDT
0.2793
-0.0124 (-4.25%)
After-hours: Sep 12, 2025, 7:59 PM EDT
Genprex Employees
Genprex had 15 employees as of December 31, 2024. The number of employees decreased by 11 or -42.31% compared to the previous year.
Employees
15
Change (1Y)
-11
Growth (1Y)
-42.31%
Revenue / Employee
n/a
Profits / Employee
-$1,170,871
Market Cap
9.76M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | -11 | -42.31% |
| Dec 31, 2023 | 26 | -2 | -7.14% |
| Dec 31, 2022 | 28 | 11 | 64.71% |
| Dec 31, 2021 | 17 | 5 | 41.67% |
| Dec 31, 2020 | 12 | 4 | 50.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GNPX News
- 11 days ago - Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - PRNewsWire
- 26 days ago - Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers - PRNewsWire
- 5 weeks ago - Genprex Issues Stockholder Letter and Provides 2025 Corporate Update - PRNewsWire
- 2 months ago - Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - PRNewsWire
- 2 months ago - Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions - PRNewsWire
- 3 months ago - Genprex to Participate at BIO 2025 International Convention - PRNewsWire
- 3 months ago - Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - PRNewsWire
- 3 months ago - Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - PRNewsWire